Praxis Precision Medicines, Inc. PRAX Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
- Praxis Precision Medicines, Inc. (PRAX) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value of $454.08M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value changed year-over-year?
- Praxis Precision Medicines, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value increased by 40551.3% year-over-year, from $1.12M to $454.08M.